#United States #INOVIO #DNA medicines #Plymouth Meeting #HPV

INOVIO's Upcoming Scientific Conference Participation

Introduction
INOVIO Pharmaceuticals, a leading figure in the biotechnology sector, is gearing up for a significant presence at two of the most anticipated scientific conferences in the coming weeks. This participation represents a critical opportunity for INOVIO to share its groundbreaking innovations in DNA-based medicines aimed at combating HPV-related diseases and various infectious ailments.

Upcoming Events

Eurogin HPV Conference

Date: March 19, 2026
Location: Vienna, Austria
Presentation: "DNA Immunotherapy INO-3107: Demonstrates Long-Term Surgical Intervention Reduction in HPV-6/11 RRP"
At the Eurogin HPV Conference, INOVIO will present exciting findings related to its investigational treatment, INO-3107. This session will delve into how this novel immunotherapy can potentially reduce the need for surgical interventions in patients suffering from recurrent respiratory papillomatosis (RRP) caused by HPV types 6 and 11. The preliminary data suggests a promising step forward in the fight against HPV, providing hope for enhanced treatment paradigms.

World Vaccine Congress DC

Date: March 30, 2026
Location: Washington, D.C.
Presentation: "Novel DNA-Encoded Monoclonal Antibody Technology: Durable and Tolerable In Vivo Expression of mAbs Targeting COVID-19"
Following its presence in Europe, INOVIO will transition to the World Vaccine Congress in Washington, D.C., where the focus will shift to its advanced DNA-encoded monoclonal antibody technology. The presentation aims to discuss its potential impact on COVID-19 treatment and prevention, showcasing the capacity for sustained and tolerable expression of monoclonal antibodies in human subjects. This innovative approach could revolutionize how vaccines and therapies are developed, particularly in the face of emerging infectious diseases.

In-depth Look at INOVIO's Innovations

INOVIO is at the forefront of developing and commercializing DNA medicines that are designed to bolster the body’s immune response to a range of diseases including HPV, various cancers, and infectious conditions. By utilizing their proprietary technology, INOVIO aims to teach the human body to produce its own therapeutic agents, enhancing the fight against diseases in ways traditional treatment methods have not achieved.

The company's commitment to research and innovation is further evidenced by its pipeline of DNA medicines, which are meticulously designed to optimize therapeutic efficacy while minimizing potential side effects. This is critical in ensuring that treatments are not only effective but also safe for patients.

Conclusion

As INOVIO prepares for these vital conferences, the biotechnology community and patients alike will be looking forward to the insights and data that will emerge. The presentations promise to shine a light on promising advancements in medical science, underscoring INOVIO's commitment to transforming the future of healthcare and disease prevention. Stay tuned for further updates and details on their presentations, which will be made available on INOVIO's official website post-conferences.

About INOVIO

INOVIO Pharmaceuticals is a biotech company dedicated to developing and commercializing its innovative DNA medicines that target HPV-related diseases, cancers, and infectious diseases. INOVIO’s focus on optimizing design and delivery has positioned it as a leader in creating effective treatments that empower the body’s immune system against disease. For more information, visit www.inovio.com.

Contact Information
For media inquiries:
Jennie Willson
Phone: (267) 429-8567
Email: [email protected]

For investors:
Peter Vozzo
ICR Healthcare
Phone: (443) 213-0505
Email: [email protected]